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Background: Adequate selection of patients with peritoneal metastasis (PM)
for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemo-
therapy (HIPEC) remains critical for successful long-term outcomes. Factors
reflecting tumor biology are currently poorly represented in the selection
process. The prognostic relevance of RAS/RAF mutations in patients with PM
remains unclear.
Methods: Survival data of patients with colorectal PM operated in 6 Euro-
pean tertiary centers were retrospectively collected and predictive factors for
survival identified by Cox regression analyses. A simple point-based risk
score was developed to allow patient selection and outcome prediction.
Results: Data of 524 patients with a median age of 59 years and a median
peritoneal cancer index of 7 (interquartile range: 3–12) were collected. A
complete resection was possible in 505 patients; overall morbidity and 90-day
mortality were 50.9% and 2.1%, respectively. PCI [hazard ratio (HR): 1.08],
N1 stage (HR: 2.15), N2 stage (HR: 2.57), G3 stage (HR: 1.80) as well as
KRAS (HR: 1.46) and BRAF (HR: 3.97) mutations were found to significantly
impair survival after CRS/HIPEC on multivariate analyses. Mutations of RAS/
RAF impaired survival independently of targeted treatment against EGFR.
Consequently, a simple point-based risk score termed BIOSCOPE (BIOlogi-
cal Score of COlorectal PEritoneal metastasis) based on PCI, N-, G-, and RAS/
RAF status was developed, which showed good discrimination [development
area under the curve (AUC) ¼ 0.72, validation AUC ¼ 0.70], calibration (P¼
0.401) and allowed categorization of patients into 4 groups with strongly
divergent survival outcomes.
Conclusion: RAS/RAF mutations impair survival after CRS/HIPEC. The
novel BIOSCOPE score reflects tumor biology, adequately stratifies long-
term outcomes, and improves patient assessment and selection.
Keywords: colorectal carcinoma, cytoreductive surgery (CRS),
hyperthermic intraperitoneal chemotherapy (HIPEC), KRAS/NRAS/BRAF,
peritoneal metastasis
(Ann Surg 2018;268:845–853)
P eritoneal metastasis (PM) from colorectal carcinoma (CRC)carries a worse prognosis than other isolated distant metastases
of CRC.1 Over the last years, the combination of effective systemic
therapy in combination with cytoreductive surgery (CRS) and hyper-
thermic intraperitoneal chemotherapy (HIPEC) improved cancer-
specific survival (CSS) in patients with PM.2 Although it has been
shown that this invasive procedure can be performed with acceptable
mortality and morbidity rates,3 selection of patients is critical to
avoid unnecessary procedures in patients, who do not benefit from
CRS/HIPEC.4 Multiple factors influence successful postoperative
long-term oncological outcomes, for example, the completeness of
resection5 or the absence of major postoperative complications.6,7
However, the role of tumor biology and RAS/RAF mutations in
the context of PM remains unclear. RAS/RAF proteins work as
downstream secondary messengers of the epidermal growth factor
receptor (EGFR) which is expressed on 85% of patients with
metastatic CRC.8 RAS mutations belong to the hallmark character-
istics of CRC and affect between 30% to 50% (KRAS) and 3% to 5%
(NRAS) of patients with metastatic CRC,8,9 whereas mutations of
BRAF are found in 3% to 10%9–13 and are mutually exclusive with
RAS mutations.13,14 Antibodies blocking EGFR (Cetuximab and
Panitumumab) and small-molecule inhibitors (Erlotinib and Gefiti-
nib), preventing intracellular tyrosine kinase activation, were devel-
oped to counteract activation of RAS/RAF proteins and their
downstream targets.15 They modestly improve overall- and recur-
rence-free survival (RFS), when given alone or in combination with
standard regimens.16,17 In patients with PM of colorectal origin, the
role of RAS/RAF mutations has not been examined and might be
helpful to predict survival after CRS/HIPEC in combination with
other prognostic factors. Available scores18 and nomograms19 are
complex, and show a moderate ability to predict the outcome of
patients after CRS/HIPEC.20 Currently, there is no preoperative
scoring system which incorporates tumor biology as a prognostic
factor and accurately predicts oncological outcomes. The primary
aim of our current analyses was therefore to investigate the role
RAS/RAF on CSS and RFS in patients undergoing CRS/HIPEC.
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Secondary goal was to develop a sore based on tumor biology-related
factors to adequately predict oncological outcomes.
METHODS
Patients and Ethics
The study was approved by the lead ethics committee of the
cantonal authorities in Zurich, Switzerland (KEK-ZH-Nr. 2017-
01656) and the respective local authorities (Supp. Info. 1, http://
links.lww.com/SLA/B449). Data of patients with PM from colorectal
cancer from 6 European centers (Zurich, St. Gallen, and Lausanne,
Switzerland; Lyon, France; Murcia, Spain; and Vienna, Austria) were
collected and analyzed. Latest follow-up data including dates of
death or recurrences and further oncological therapies were obtained
from the hospital databases or by directly contacting patients or
oncologists.
Treatment
Patients were presented at multidisciplinary tumor boards at the
respective institutions and selected for CRS/HIPEC after clinical
workup and exclusion of extra abdominal tumor manifestations by
18FDG-PET/CT or thoracic-abdominal CT. Patients received standard
of care pre- and postoperative chemotherapy according to international
guidelines, based on leucovorin, 5-fluorouracil, irinotecan, and/or
oxaliplatin, in combination with targeted therapies (monoclonal anti-
bodies or small molecule inhibitors targeting VEGFa/angiogenesis or
EGFR) where appropriate. CRS/HIPEC was performed by experi-
enced and trained surgeons in all centers as specified elsewhere.21,22
Mitomycin C sole [15–30 mg/m2 Body Surface Area (BSA)] or in
combination with doxorubicin (15 mg/m2 BSA) at 428C for 90 minutes
or oxaliplatin (300–400 mg/m2 BSA) as single agent at 438C for 30
minutes were used for HIPEC. A procedure was defined as curative, if
radical CRS (CC-Score 0,23 no macroscopic residual tumor) followed
by HIPEC could be performed.
Pathology
PCI was calculated after careful inspection following laparot-
omy at the beginning of CRS/HIPEC. Information on TNM-stage, G-
stage, histology, and RAS/RAF status was retrieved from pathology
reports of the operating hospital or referral letters and previous
pathology reports.
Statistical Analyses and Risk Score Development
All statistical analyses were performed with R (Supp. Info. 2,
http://links.lww.com/SLA/B449). Continuous data are reported as
median (m) and interquartile range (IQR). Wilcoxon rank-sum test or
Fisher exact test were used to compare medians, resp. frequencies
between groups. Statistical significance was defined as P < 0.05.
CSS and RFS were calculated with Kaplan–Meier estimates from the
date of the operation until date of cancer-related death, disease
progression or date of last follow up in months. Mantel–Cox log-
rank test was used to test for differences between survival times with
Bonferroni correction for multiple comparisons. A total of 1000
bootstrapped samples were used to calculate 95% confidence inter-
vals (CIs) of all measures or standard error (SE) of regression
coefficients. Uni- and multivariate analyses were performed with
Cox’s proportional hazard regression models; predictors with a P
value of less than 0.1 were included in the multivariate model.
Missing values of categorical data were grouped into a category
‘‘Non-determined’’ for Cox regression and risk score development
with b-coefficients of respective groups not reported; no exclusion
due to missing data nor data imputation was performed.24
The risk score was developed according to the TRIPOD
guidelines25 by splitting the patient cohort randomly into a
development (70%–75% of patients) and validation (25%–30%
of patients) cohort (type 2A). A Cox regression model of factors
identified in multivariate analyses was afterward fitted to the devel-
opment cohort. The discriminative ability of the model was assessed
in the development and validation cohort with receiver-operating
characteristic (ROC) curves and corresponding area under the curve
(AUC) values of 1000 bootstrapped samples at fixed time points,
whereas Nagelkerke R2 values served as parameter of the explained
variability of the model. Calibration of observed survival frequencies
and predicted survival probability of the model were performed with
the jackknife pseudo-value method and evaluated by the Grønnesby
and Borgan goodness-of-fit test.26 A shrinkage factor was calculated
via 10-fold internal cross validation on the development cohort to
reduce the risk of model over-fitting. Consequently, whole integers
were assigned to risk factor levels by dividing shrinkage-adjusted
regression b-coefficients by a predetermined constant B according to
previous studies.27,28 The derived score was afterward applied to
both cohorts for internal validation.
RESULTS
Patient Characteristics
Data of 524 patients operated between January 2005 and
December 2017 were collected and analyzed. Table 1 summarizes
details of patient demographics, clinicopathological, and treatment
characteristics.
Surgical and Oncological Treatment
Most patients (78.63%) received preoperative irinotecan- or
oxaliplatin-based systemic chemotherapy regimens; 40% of patients
received additional anti-EGFR or anti-VEGF treatment. A complete
resection was reported in 96.37% of patients with a median PCI of 7
(IQR 3–12). The overall recorded complication rate after CRS/
HIPEC was 51%, whereas major complications, defined according
to the Clavien-Dindo classification as grade  IIIA,29 occurred in
16.9% of patients. The reoperation rate was 10.2% and 11 patients
died during the postoperative course. Postoperative systemic che-
motherapy was performed in 61% of patients during follow-up.
Patient Survival and Prognostic Factors
The latest follow-up data were received on the January 31, 2018.
Mean follow-up at the time of analysis was 27 months, with 204
(38.39%) patients succumbing to their disease and 375 (71.56%)
patients experiencing disease progression. Patients after complete
CRS/HIPEC showed an mCSS of 45 months (CI: 38–52) and mRFS
of 12 months (CI: 11–13, Supp. Fig. 1, http://links.lww.com/SLA/
B449). All further analyses were performed on patients after complete
CRS/HIPEC without lethal postoperative complication (n ¼ 494).
In multivariate analysis, PCI (HR 1.08 per additional point),
N1-stage (HR 2.15), N2-stage (HR 2.57), and G3-stage (HR 1.80)
were confirmed as factors predicting impaired CSS after radical
CRS/HIPEC (Table 2). KRAS (HR 1.46) and BRAF (HR 3.97)
mutations were identified as novel factors for impaired survival
(Fig. 1A). PCI (HR 1.05), N2-stage (HR 1.55), and KRAS mutations
(HR 1.42) were risk factors for shorted RFS (Fig. 1B, Supp. Table 1,
http://links.lww.com/SLA/B449).
RAS/RAF Mutational Status in the Setting of
Multimodal Therapy
To determine if the observed differences in CSS between RAS/
RAF wild-type and mutated patients are due to intrinsic tumor biology
or related to therapy with targeted therapies against EGFR, patients
with known RAS/RAF status (n ¼ 378) were divided in 3 groups:
patients with RAS/RAF mutations (n ¼ 186), patients with wild-type
RAS/RAFwhich received chemotherapy without anti-EGFR treatment
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(n ¼ 115), and patients with wild-type RAS/RAF treated with anti-
EGFR treatment (n ¼ 77) (Fig. 1C). Interestingly, patients with wild-
typeRAS/RAFhad improved survival regardless of treatment with (P¼
0.047) or without (P¼ 0.028) targeted anti-EGFR treatment compared
with patients with RAS/RAF mutations, indicating a mutation-caused
rather than treatment-related effect on survival.
Development of a New Risk Score for Patient
Selection Based on Tumor Biology
Randomized splitting allocated 358 (72.4%) patients into the
development cohort and 136 (27.6%) patients into the validation
cohort (Fig. 2A). A Cox regression model with the four identified
predictive factors PCI, N-, G-, and RAS/RAF mutation status was
consequently fitted to the development cohort, which discriminated
survival at 36 months with a AUC-value of 0.72 in the development
cohort (Fig. 2B) and 0.70 in the validation cohort (Fig. 2C). The good
discrimination of >0.7 was consistent over all time points tested
TABLE 1. Baseline Patient Demographic, Clinicopathological,
and Treatment Characteristics of 524 Patients Undergoing
CRS/HIPEC for PM of Colorectal Origin
Variable n (%)
Sex
Male 257 (49.1%)
Female 267 (50.9%)
Age, yr 59 (50–66)
T-stage of the primary tumor
T3 119 (22.7%)
T4 213 (40.7%)
Tx/not available 192 (36.6%)
N-stage of the primary tumor
N0 85 (16.2%)
N1 119 (22.7%)
N2 131 (25.0%)
Nx/not available 189 (36.1%)
G-stage/histological grading
G1 90 (17.2%)
G2 211 (40.3%)
G3 88 (16.8%)
Gx/not available 135 (25.7%)
Histological subtype
Intestinal adenocarcinoma 401 (76.5%)
Mucinous adenocacinoma 62 (11.8%)
Signet-ring cell adenocarcinoma 37 (7.1%)
Not available 24 (4.6%)
Tumor localization
Caecum 57 (10.9%)
Colon ascendens 123 (23.5%)
Colon transversum 22 (4.2%)
Colon descendens 82 (15.6%)
Sigmoid colon 195 (37.2%)
Rectum 36 (6.9%)
Not available 9 (1.7%)
Appearance of PM
Synchronous 283 (54.0%)
Metachronous 241 (46.0%)
RAS/RAF mutations
Wild-type 202 (38.5%)
KRAS mutation 154 (29.5%)
NRAS mutation 24 (4.6%)
BRAF mutation 20 (3.8%)
Not available 154 (29.4%)
Center
Lausanne 15 (2.7%)
Lyon 363 (69.3%)
Murica 25 (5.0%)
St. Gallen 33 (6.3%)
Vienna 17 (3.3%)
Zurich 70 (13.4%)
PCI
PCI 0–5 212 (40.5%)
PCI 6–10 163 (31.1%)
PCI 11–15 55 (10.5%)
PCI 16–20 56 (10.6%)
PCI 21–25 29 (5.4%)
PCI 26–30 7 (1.3%)
PCI 31–35 1 (0.2%)
PCI 36–39 1 (0.2%)
Median PCI (þIQR) 7 (3–12)
HIPEC regimen
Oxaliplatin 266 (50.8%)
Mitomycin C/Doxorubicin 44 (8.4%)
Mitomycin 171 (32.6%)
Other/not documented 43 (8.2%)
(Continued )
TABLE 1. (Continued)
Variable n (%)
Operation time, min 308 (240–420)
Not available 179
Bloodloss, mL 300 (112.5–537.5)
Not available 458
Postoperative ICU stay, d 1 (1–2)
Not available 9
Postoperative hospital stay, d 16.5 (13–25)
Not available 6
OP potentially curative treatment
Yes 505 (96.4%)
No 19 (3.6%)
Complications according to
Clavien-Dindo classification
None 257 (49.1%)
Grade 1 45 (8.6%)
Grade 2 133 (25.4%)
Grade 3a 32 (6.1%)
Grade 3b 24 (4.6%)
Grade 4a 17 (3.2%)
Grade 4b 5 (0.9%)
Grade 5 11 (2.1%)
Comprehensive complication index
(Slankamenac, Ann Surg, 2013)
20.9 (20.9–34.4)
Pre-HIPEC chemotherapy
No chemotherapy 112 (21.4%)
Conventional chemotherapy only 176 (33.6%)
No. of cycles 6 (4–9)
Chemotherapy þ anti-VEFGa treatment 152 (29.0%)
No. of cycles 6 (4–9.5)
Chemotherapy þ anti-EGFR treatment 74 (14.1%)
No. of cycles 5 (4–7)
Chemotherapy þ multiple targeted therapies 10 (1.9%)
No. of cycles 12 (6.5–12)
Post-HIPEC chemotherapy
No chemotherapy 205 (39.1%)
Conventional chemotherapy only 165 (31.5%)
No. of cycles 6 (5–8)
Chemotherapy þ anti-VEFGa treatment 85 (16.2%)
No. of cycles 6 (5–8.5)
Chemotherapy þ anti-EGFR treatment 50 (9.5%)
No. of cycles 7 (5–9)
Chemotherapy þ multiple targeted therapies 19 (3.7%)
No. of cycles 6 (5–11.5)
CRS indicates cytoreductive surgery; HIPEC, hyperthermic intraperitoneal
chemotherapy; PM, peritoneal metastasis.
Continuous variables are shown as median and interquartile range.
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(Supp. Fig. 2A, http://links.lww.com/SLA/B449). Comparison of
observed survival frequencies and predicted survival probabilities
at 36 months (Fig. 2D) and additional time points (Supp. Fig. 2B and
C, http://links.lww.com/SLA/B449) confirmed the good calibration
of the model in the development (goodness-of-fit test: P ¼ 0.401) as
well as validation cohort (goodness-of-fit test: P ¼ 0.483). Cross-
validation yielded a global shrinkage coefficient of 0.9098. Using the
shrinkage-adjusted b regression coefficients for allocation of points
to the respective factors levels, the risk score with a range of 0 to 12
points was calculated (Fig. 3A). The resulting score was conse-
quently applied on development and validation cohort and showed a
consistent stepwise decrease of mCSS with increasing amount of
points (Fig. 3B and C). In a last step, 4 risk groups were defined based
on the allocated points. Patients with a risk score of 0 (risk group A)
showed excellent long-term outcomes. Patients with minimal (1–3)
risk points had a median survival over the average of 43 months of the
whole cohort and were defined as risk group B. Patients with
intermediate risk scores between 4 and 7 (risk group C) showed
an acceptable survival after CRS/HIPEC, whereas patients with risk
scores 8 and higher (risk group D) had a dismal long-term outcome
(Fig. 3D and E); the score also allowed stratification of PFS in both
cohorts to a certain extent (Supp. Fig. 3A and B, http://links.
lww.com/SLA/B449).
DISCUSSION
The present study for the first time identifies mutations of
RAS/RAF oncogenes as a risk factor for overall survival after CRS/
HIPEC in patients with colorectal PM. In addition, we present a novel
score (BIOSCOPE) to stratify patients with colorectal PM before
CRS/HIPEC.
The role of RAS/RAF mutations in CRC is known as a
surrogate marker for response rates to targeted chemotherapy30
and overall survival in the setting of palliative chemotherapy.31 In
patients with CRLM, RAS mutations are a prognostic factor32,33,34
and were included in a newly proposed modified version of the
Clinical Risk Score for Prediction of Recurrence after resection of
CRLM.35 In contrast, its role as a predictive factor in patients
TABLE 2. Uni- and Multivariate Analysis of Factors Predicting Cancer-specific Survival (CSS) in Patients With PM of Colorectal
Origin After Complete CRS/HIPEC (n ¼ 494)
Univariate Analysis Multivariate Analysis
Variable n (%) Median CSS, mo (95% CI) Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Sex
Male 236 (47.8%) 50 (35–65)
Female 258 (52.2%) 43 (35–53) 1.17 (0.87–1.57) 0.284
Age (per additional year) 0.98 (0.97–0.99) 0.046 0.98 (0.97–1.00) 0.405
Year of CRS/HIPEC
2005–2012 193 (39.1%) 45 (40–50)
2013–2017 301 (60.9%) 44 (34–53) 1.18 (0.86–1.63) 0.299
T-stage
T3 113 (36.4%) 45 (26–63)
T4 197 (63.6%) 38 (28–48) 1.23 (0.85–1.79) 0.259
N-stage
N0 80 (25.6%) 57 (51–62)
N1 111 (35.5%) 36 (26–45) 2.24 (1.28–3.95) 0.004 2.15 (1.18–3.90) 0.011
N2 122 (39.0%) 36 (27–46) 2.91 (1.70–4.98) 0.001 2.57 (1.47–4.49) 0.001
G-stage
G1 86 (23.6%) 51 (38–65)
G2 200 (55.0%) 45 (30–60) 0.92 (0.62–1.38) 0.714 1.09 (0.71–1.67) 0.672
G3 78 (21.4%) 31 (22–40) 1.84 (1.17–2.90) 0.008 1.80 (1.06–3.05) 0.028
Histology
Adenocarcinoma 380 (80.5%) 47 (39–54)
Mucinous adenocarcinoma 61 (12.9%) 49 (23–75) 1.21 (0.78–1.89) 0.385 1.19 (0.69–2.04) 0.526
Singet ring cell 31 (6.6%) 34 (21–47) 1.86 (1.05–3.30) 0.032 1.07 (0.56–2.04) 0.835
Localisation
Coecum/ascendens 171 (35.2%) 36 (29–43)
Transversum/descendens 99 (20.4%) 77 (40–104) 0.59 (0.40–0.86) 0.001 0.67 (0.42–1.04) 0.073
Rectosigmoid 216 (44.4%) 51 (39–63) 0.73 (0.54–0.97) 0.003 0.78 (0.55–1.09) 0.155
Temporal appearance of PM
Synchronous 268 (54.3%) 41 (33–49)
Metachronous 226 (45.7%) 48 (39–57) 0.85 (0.63–1.15) 0.302
PCI per additional point 1.08 (1.06–1.10) 0.001 1.08 (1.06–1.10) 0.001
RAS/RAF mutation
Wildtype 192 (50.8%) 52 (40–65)
KRAS mutation 145 (38.4%) 38 (31–46) 1.45 (1.02–2.07) 0.036 1.46 (1.00–2.12) 0.048
NRAS mutation 19 (5.0%) 49 (19–80) 1.22 (0.65–2.33) 0.533 0.88 (0.45–1.72) 0.711
BRAF mutation 22 (5.8%) 18 (9–26) 4.29 (2.16–8.51) 0.001 3.97 (1.86–8.44) 0.001
Major complication (Clavien Dindo classification 3A)
No major complication 421 (85.2%) 49 (40–57)
Major complication 73 (14.8%) 38 (27–49) 1.53 (1.05–2.23) 0.026 1.20 (0.78–1.84) 0.406
CI indicates confidence Interval; CRS, cytoreductive surgery; CSS, cancer-specific survival; HIPEC, hyperthermic intraperitoneal chemotherapy; IQR, interquartile range; PCI,
peritoneal cancer index; PM, peritoneal metastasis.
Significant values are in bold letters.
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undergoing surgery for PM, which are known to have a worse
prognosis than liver or lung metastasis, is unclear.1 In the present
study, we are able to demonstrate the specific influence of RAS/RAF
mutations on CSS and RFS in patients with PM from CRC undergo-
ing CRS/HIPEC. We found impaired CSS and PFS after CRS/HIPEC
for KRAS mutations, a heavy impact on CSS for BRAF mutations,
whereas NRAS mutations did only impact on PFS in our cohort.
Differences between KRAS, NRAS, and BRAF mutations in postsur-
gical outcomes have so far not been described.
Our analysis confirmed other predictive factors, for exam-
ple, the amount of peritoneal disease, assessed by the PCI,
positive lymph node status of the primary tumor, and tumor
grading.36,37 We consequently included PCI, N-, G-, and RAS/
RAF mutational status in a Cox model, which showed good
discrimination and calibration on the development as well as the
validation cohort. We finally developed a score with a maximum
of 12 points, which we termed BIOSCOPE (BIOlogical Score
of COlorectal PEritoneal metastasis). When applied to both our
cohorts, increasing score numbers strongly correlated with
decreasing survival.
We then determined 4 groups based on points: BIOSCOPE A
(0 risk points) represents patients with absent risk factors (PCI 10,
N0, G1–2, RAS/RAF wt). These patients can expect an excellent
long-term outcome, reflected by mCSS of 70 and 65 months in our
cohorts. BIOSCOPE B (1–3 risk points) reflects patients with
moderate risk factors; these patients are able to reach mCSS of
50 and 39 months respectively, which is equal and above the mCSS of
40 to 45 months reported in recent analyses of patients undergoing
CRS/HIPEC.6,7 BIOSCOPE C patients (4–7 points) profit from
CRS/HIPEC with a mCSS of 33 and 25 months, which is clearly
superior to the mCSS of 16.9 months in patients with PM treated
systemically with modern targeted chemotherapy only.1 In contrast,
BIOSCOPE D patients (8 points) show a dismal survival of 13
(development) and 7 (validation) months only. CRS/HIPEC in these
patients should be evaluated critically regarding possible complica-
tions and time for convalescence, and the decision for CRS/HIPEC
should be made carefully on an individual basis.
We would like to acknowledge the limitations of our study.
External validation is currently lacking and must be performed in an
additional, independent patient cohort to confirm the value of the
FIGURE 1. The influence of RAS/RAFmutations on outcomes after CRS/HIPEC. (A)While patients without RAS/RAFmutations show a
median CSS of 52 months (CI: 40–65), outcomes for patients with KRASmutations (mCSS 38 mo, CI: 31–46, P ¼ 0.036) and BRAF
mutations (mCSS of 21mo, CI: 9–26, P0.001) were strongly impaired. No significant effect ofNRASmutations (mCSS: 51mo, CI:
19–80, P¼ 0.533) on CSS was observed. (B) Similarly, median RFS was reduced by 4 months for patients with KRASmutations (P¼
0.007), 3 months for NRAS mutations (P ¼ 0.032) and 7 months (P ¼ 0.051) for BRAF mutations compared with 15 months in
unmutated patients. (C) The survival benefit of patients with wildtype RAS/RAF remained also if they were only treated with
conventional chemotherapy without anti-EGFR treatment (mCSS 48mo, CI: 40–83) compared with 37months (CI: 31–46) only in
patients with mutant RAS/RAF (P ¼ 0.028). Patients with wildtype RAS/RAF and treatment with anti-EGFR therapy showed a mCSS
of 53 months (CI: 42–64) without difference to wildtype patients with conventional chemotherapy only (P ¼ 0.820).
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FIGURE 2. Discrimination and calibration of Cox regressionmodel. (A) Methodological flow schema of patient cohort analyses and
random splitting into development and validation cohort. (B) The Cox regression model with the 4major predictive factors PCI, N-,
G-, and RAS/RAFmutation status predicted survival at 3 years in the development cohort with a AUC value of 0.72 (CI: 0.65–0.80,
R2: 0.167) and showed superior discrimination compared to models consisting of the single predictive factors PCI (AUC: 0.65, R2:
0.093), N-status (AUC: 0.59, R2: 0.03), G-status (AUC: 0.57, R2: 0.028), or RAS/RAF mutational status (AUC: 0.64, R2: 0.031) only.
(C) Consequent application of the model on the validation cohort confirmed the good discriminative ability with an AUC ¼ 0.70.
(D) Observed survival frequencies and predicted survival probabilities at 3 years after CRS/HIPEC for quintiles of survival groups
confirmed the strong calibration of the model in both cohorts.
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BIOSCOPE score for patient selection and classification. Internal
validation in this study was performed by splitting the cohort into a
development and validation cohort.
Preoperative determination of the PCI remains challenging,
despite modern imaging by MRI, CT, or PET. Therefore, most
centers performing CRS/HIPEC for CRC advocate to perform
laparoscopy to assess the PCI before CRS/HIPEC. The PCI docu-
mented in our study was evaluated on explorative laparotomy. For the
development of our score, we decided to separate the PCI in
relatively large categories of 10 points to facilitate preoperative
classification of patients based on laparoscopy.
Information regarding RAS status of patients was based on the
available retrospective data and no additional analysis of existing
tumor tissue was performed. Most patients received testing of KRAS,
but not NRAS or BRAF. Mutations of KRAS are the most frequent9,11
and normally mutually exclusive toward mutation of NRAS or
BRAF38–40 and therefore render further testing unnecessary. How-
ever, in cases of absent KRAS mutation, it is nowadays recommended
to consequently test for mutations in NRAS,9 BRAF,9,10 and most
recently PI3KCA (mutated in 3.5% of CRC),9,11 which all lead
activation of EGFR downstream signals and render the patient
resistant to anti-EGFR therapy. As additional retrospective testing
of NRAS and BRAF was not possible, there might be the potential
bias that patients without KRAS mutation were grouped in the wild-
type group although being NRAS or BRAF mutated. Despite this, we
consider this potential bias as negligible as rates of RAS/RAF
FIGURE 3. BIOSCOPE risk score development & internal validation. (A) A point-based risk score termed BIOSCOPE was developed
by dividing shrinkage-adjusted b regression coefficients through constant B. Points were rounded to the next integer. (B) Application
of the score on our development cohort showed a consistent decrease of mCSS with increasing risk points. Four risk groups were
defined based on similar survival. Patients with 0 risk points showed excellent long-term outcome with a mCSS of 70 months;
patients with risk score between 1 and 3 hadmCSS above themedian of the whole cohort (43mo) andwere defined as risk group B.
Patients with risk scores between 4 and 7 (risk group C) showed an acceptable survival, whereas patients with risk scores 8 and higher
(risk group D) had a dismal long-term outcome similar or below the current survival reached by systemic palliative chemotherapy.
(C) Risk point allocation to the validation cohort confirmed decreasing survival with increasing risk points. (D) Application of the risk
score with consequent group allocation divided patients in the development cohort into groups with strongly divergent outcomes
of 70 months CSS (CI: 58–82) for group A, 55 months (CI: 42–68) for group B, 33 months (CI: 24–41) for group C, and 13months
(CI: 5–24) for group D (P0.001 for all comparisons between the 4 groups). (E) The score confirmed its value for stratification of
patient outcomes after CRS/HIPEC by dividing patients in the validation cohort into 4 groups with mCSS of 65 months (CI: 43–87)
for group A, 39months (CI: 27–51) for group B, 25 (CI: 16–33) for group C, and 7 (CI: 5–9) for group D (P0.01 for all comparisons
between the 4 groups).
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mutations in our patient sample compare well to the rates found in
patients with CRC in systematic analyses. We therefore believe that
our patient cohort represents an adequate sample of CRC patients.
CONCLUSION
Mutations of KRAS, and in particular BRAF, are negative
prognostic factors in patients with PM of CRC undergoing CRS/
HIPEC. The novel BIOSCOPE score, including RAS/RAF mutational
status, PCI, and N- and G-status of the primary tumor, adequately
predicts prognosis of patients, which can help to improve patient
selection.
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DISCUSSANTS
Beat P. Mu¨ller (Heidelberg, Germany):
I would like to thank and congratulate you for your innovative
idea to develop the BIOSCOPE score, which should help us select
patients for cytoreductive surgery and HIPEC for peritoneal metas-
tasis originating from colorectal cancer in the future. Such a score is
of great interest for both the surgical and oncological community. I
very much appreciate the careful and thorough work you invested in
this important idea.
First, I somewhat regret that you did not focus on this idea, and
instead, spent most of the study introducing and discussing the
importance of RAS/RAF proto-oncogenes as a predictive factor,
which results in the fact that the BIOSCOPE score is not even
mentioned in the title of the manuscript. From a surgical point of
view – and Annals of Surgery is a surgical journal – a score, which
helps us to better select surgical patients, would be of major interest.
Could you please comment on this?
Second, unfortunately, external validation is missing, and
therefore, the score cannot be generally recommended as a valid
prognostic stratification tool for the time being. This should be stated
in the conclusions, abstract, mini-abstract, and manuscript. The
opportunity to address this flaw would have been to use a nonrandom
split sample (TRIPOD 2B) – for example, the Lion population – for
validation. Why did you decide against this? Unfortunately, accord-
ing to the TRIPOD statement, using a random split-sample does not
improve score development and validation compared with TRIPOD
1B, which you applied in the first version of your manuscript.
Third, how can we know that the BIOSCOPE score provides
any improvement, in terms of the prediction of prognosis and better
patient selection, when compared with existing selection criteria,
such as the peritoneal carcinosis index or others?
Fourth, how did you deal with other potential confounders and
risk factors, which have not been mentioned so far, such as different
histologies, chemotherapy regimes, surgical expertise, changed man-
agement during the investigated period and so on? This should at
least be mentioned in the supplemental material.
Response From Kuno Lehmann (Zurich,
Switzerland):
Thank you, Professor Mu¨ller, for your interesting questions.
There is a big discussion around the biology among different types
of metastases, for example, lung, liver, or peritoneal metastases.
Our main goal here was to explore the biology of peritoneal
metastasis. This is why I personally think that the identification
of novel risk factors, for example, K-RAS or B-RAF, is of major
importance. BIOSCOPE is a useful tool that was developed after-
ward and will improve decision-making in the treatment of perito-
neal metastasis.
Regarding your second question, the critical point here is
external validation, and I acknowledge and agree with your point that
this study needs independent external validations. I think that this is
absolutely clear, and I’d be happy to welcome everyone, who would
join us here and help us further develop BIOSCOPE.
Your third comment is very important. The peritoneal cancer
index, PCI, is a known major predictor of survival in patients with
peritoneal metastasis. The point here is that the surgeons operating
these patients learned this already and tend to select patients in a
quite narrow range of PCI. In our study, the median PCI ranged from
3 to 12, and 70% of patients were below 10. If the PCI range is
narrowed in patients selected for surgery, then we need further
parameters to predict outcomes, and I think our work can be of
interest and help.
Regarding your last question, CRS/HIPEC was performed in
all centers by qualified surgeons, and we did not observe any
difference in survival among the institutions. We also analyzed
factors, such as tumor histology or preoperative chemotherapy.
For example, signet cell histology was significant in the univariate
analysis, but not in the multivariate analysis. We did not find any
significance for preoperative chemotherapy, which was applied in
80% of our patients.
Christiane Bruns (Cologne, Germany):
Basically, with the BIOSCOPE score, you tried to gain further
information to select patients for cytoreductive surgery and HIPEC,
with peritoneal metastasis originating from colorectal cancer beyond
the PCI score. Did you integrate the location of the primary tumor as
a confounder within the BIOSCOPE score, since the distribution of
the mutations of the RAS/RAF proto-oncogenes is different? This
automatically leads me to the next question: Did you integrate the
impact of different chemotherapies and biologicals in the develop-
ment of the BIOSCOPE score?
Response From Kuno Lehmann (Zurich,
Switzerland):
Thank you, Professor Bruns, for your interesting question. We
looked at the influence of the site of the primary tumor, but did not
identify a predictive role. We also looked at different types of chemo-
therapies and the addition of VEGF antibodies, which did not have a
significant impact. Importantly, the addition of EGFR antibodies did
not improve the outcome, even in K-RAS wild-type patients.
Olivier Turrini (Marseille, France):
Congratulations on this very interesting work. I have one
question. Did you look at the original location of the mutation? Was it
on Codon 12 or 13 because it has been shown in liver metastases that
recurrence rate was higher, when a K-RAS mutation occurred on
Codon 13?
Response From Kuno Lehmann (Zurich,
Switzerland):
Thank you, Professor Turrini, that is a very important ques-
tion. Unfortunately, we do not have this data. However, this would be
an interesting study for the future.
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